B.‐Y. Zeng

909 total citations
17 papers, 735 citations indexed

About

B.‐Y. Zeng is a scholar working on Cellular and Molecular Neuroscience, Neurology and Pharmacology. According to data from OpenAlex, B.‐Y. Zeng has authored 17 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 10 papers in Neurology and 2 papers in Pharmacology. Recurrent topics in B.‐Y. Zeng's work include Neurotransmitter Receptor Influence on Behavior (9 papers), Neuroscience and Neuropharmacology Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). B.‐Y. Zeng is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (9 papers), Neuroscience and Neuropharmacology Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). B.‐Y. Zeng collaborates with scholars based in United Kingdom, Singapore and China. B.‐Y. Zeng's co-authors include Peter Jenner, R. K. B. Pearce, Sarah Rose, Banu Cahide Tel, Peter Jenner, Grace Mackenzie, Carla Cannizzaro, M. Cebeira, Marı́a L. de Ceballos and Javier Fernández‐Ruíz and has published in prestigious journals such as Neuroscience, Experimental Brain Research and European Journal of Neuroscience.

In The Last Decade

B.‐Y. Zeng

16 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B.‐Y. Zeng United Kingdom 12 469 371 192 150 100 17 735
Alessandra Bonito-Oliva Sweden 16 569 1.2× 362 1.0× 69 0.4× 285 1.9× 129 1.3× 20 858
Elsa Y. Pioli France 16 562 1.2× 442 1.2× 59 0.3× 222 1.5× 164 1.6× 29 883
Melissa M. Conti United States 18 343 0.7× 339 0.9× 71 0.4× 310 2.1× 42 0.4× 22 747
Elvira Roda Spain 14 395 0.8× 186 0.5× 254 1.3× 142 0.9× 108 1.1× 24 615
Isabel Espadas Spain 11 345 0.7× 172 0.5× 64 0.3× 213 1.4× 92 0.9× 16 610
J M Masserano United States 13 489 1.0× 244 0.7× 74 0.4× 209 1.4× 102 1.0× 19 714
Elisabetta Tronci Italy 20 728 1.6× 658 1.8× 58 0.3× 199 1.3× 112 1.1× 32 1.0k
Megan J. Dowie New Zealand 7 357 0.8× 216 0.6× 205 1.1× 124 0.8× 58 0.6× 9 557
Ning-Sheng Cai United States 15 485 1.0× 82 0.2× 82 0.4× 415 2.8× 93 0.9× 21 759
Peter‐Andreas Löschmann Germany 12 643 1.4× 414 1.1× 42 0.2× 244 1.6× 67 0.7× 17 897

Countries citing papers authored by B.‐Y. Zeng

Since Specialization
Citations

This map shows the geographic impact of B.‐Y. Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.‐Y. Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.‐Y. Zeng more than expected).

Fields of papers citing papers by B.‐Y. Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.‐Y. Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.‐Y. Zeng. The network helps show where B.‐Y. Zeng may publish in the future.

Co-authorship network of co-authors of B.‐Y. Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of B.‐Y. Zeng. A scholar is included among the top collaborators of B.‐Y. Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.‐Y. Zeng. B.‐Y. Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zeng, B.‐Y., et al.. (2024). Network pharmacology and experimental validation reveals the potential therapeutic effects of Polygonum cuspidatum against odontogenic keratocyst. Journal of Stomatology Oral and Maxillofacial Surgery. 126(3). 102105–102105.
2.
Li, Jialu, Yan Zhu, Tong Zhou, et al.. (2024). Chemical constituents, pharmacology and safety of isoflavones in Puerariae Lobatae Radix. 4(4). 21–21. 3 indexed citations
3.
Zeng, B.‐Y., Andrew D. Medhurst, Michael S. Jackson, Sarah Rose, & Peter Jenner. (2005). Proteasomal activity in brain differs between species and brain regions and changes with age. Mechanisms of Ageing and Development. 126(6-7). 760–766. 89 indexed citations
4.
Zeng, B.‐Y., Simon Heales, Laura Canevari, Sarah Rose, & Peter Jenner. (2004). Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice. Experimental Neurology. 190(2). 515–524. 11 indexed citations
5.
Zeng, B.‐Y., et al.. (2003). Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets. Neuroscience Letters. 354(1). 6–9. 8 indexed citations
6.
Lyras, Leonidas, B.‐Y. Zeng, Gerald M. McKenzie, et al.. (2002). Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. Journal of Neural Transmission. 109(1). 53–67. 39 indexed citations
7.
Tel, Banu Cahide, B.‐Y. Zeng, Carla Cannizzaro, et al.. (2002). Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 115(4). 1047–1058. 73 indexed citations
8.
Zeng, B.‐Y., Brinda Dass, A Owen, et al.. (2002). 6-Hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. Neuroscience Letters. 322(1). 33–36. 11 indexed citations
9.
Zeng, B.‐Y., R. K. B. Pearce, Grace Mackenzie, & P. Jenner. (2001). Chronic high dose l -dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. Journal of Neural Transmission. 108(8-9). 925–941. 17 indexed citations
10.
Lastres‐Becker, Isabel, M. Cebeira, Marı́a L. de Ceballos, et al.. (2001). Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets. European Journal of Neuroscience. 14(11). 1827–1832. 149 indexed citations
11.
Medhurst, Andrew D., B.‐Y. Zeng, Charles Kornreich, et al.. (2001). Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment. Neuroscience. 105(2). 353–364. 8 indexed citations
12.
Jenner, P., et al.. (2000). Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Experimental Brain Research. 133(2). 178–188. 50 indexed citations
13.
Zeng, B.‐Y., R. K. B. Pearce, Grace Mackenzie, & Peter Jenner. (2000). Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA. European Journal of Neuroscience. 12(3). 1096–1104. 88 indexed citations
14.
Zeng, B.‐Y., Brinda Dass, A Owen, et al.. (1999). Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neuroscience Letters. 276(2). 71–74. 60 indexed citations
15.
Zeng, B.‐Y., et al.. (1997). Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. Journal of Neural Transmission. 104(1). 67–75. 66 indexed citations
16.
17.
Zeng, B.‐Y., Jukka Jolkkonen, Peter Jenner, & C. D. Marsden. (1995). Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 66(1). 19–28. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Bonito-Oliva Breakdown of academic impact, for papers by Elsa Y. Pioli Breakdown of academic impact, for papers by Melissa M. Conti Breakdown of academic impact, for papers by Elvira Roda Breakdown of academic impact, for papers by Isabel Espadas Breakdown of academic impact, for papers by J M Masserano Breakdown of academic impact, for papers by Elisabetta Tronci Breakdown of academic impact, for papers by Megan J. Dowie Breakdown of academic impact, for papers by Ning-Sheng Cai Breakdown of academic impact, for papers by Peter‐Andreas Löschmann
Rankless by CCL
2026